Asco 2019 – Novartis looks to premenopausal survival to reinvigorate Kisqali | Evaluate
Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epide... | OncologyPRO
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology
MONALEESA-3 OS Update - Capsule Summary Slidesets - Breast Cancer and Gynecologic Cancers - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
BOOG Study Center - Studie
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients | Novartis
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER) - European Journal of Cancer
Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials - ESMO Open
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer - LifeProNow LifeProNow
ESMO: Kisqali shows superior overall survival in breast cancer
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - European Journal of Cancer
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology
Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3 | Journal of Clinical Oncology
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - The Breast
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Kisqali extends survival by 1 year in advanced breast cancer < Pharma < 기사본문 - KBR
NEJM on Twitter: "In the MONALEESA-7 trial, ribociclib + endocrine therapy resulted in significantly longer progression-free survival than endocrine therapy alone. This article reports the results of a protocol-specified second interim analysis
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
YIR On Demand Breast Hope S Rugo, MD Professor of Medicine - ppt download
